Myocardial remodeling and pathologic hypertrophy

Karl Weber, C. G. Brilla, J. S. Janicki

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

The hallmark of myocardial hypertrophy associated with congestive failure is interstitial fibrosis. How does the fibrosis develop, and what can be done about it? Hormonal and hemodynamic factors are examined. Experimental studies with ACE inhibitors or aldosterone receptor antagonists suggest that the fibrosis may be prevented or reversed.

Original languageEnglish (US)
Pages (from-to)73-80
Number of pages8
JournalHospital Practice
Volume26
Issue number4
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Hypertrophy
Fibrosis
Mineralocorticoid Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Hemodynamics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Weber, K., Brilla, C. G., & Janicki, J. S. (1991). Myocardial remodeling and pathologic hypertrophy. Hospital Practice, 26(4), 73-80.

Myocardial remodeling and pathologic hypertrophy. / Weber, Karl; Brilla, C. G.; Janicki, J. S.

In: Hospital Practice, Vol. 26, No. 4, 01.01.1991, p. 73-80.

Research output: Contribution to journalReview article

Weber, K, Brilla, CG & Janicki, JS 1991, 'Myocardial remodeling and pathologic hypertrophy', Hospital Practice, vol. 26, no. 4, pp. 73-80.
Weber K, Brilla CG, Janicki JS. Myocardial remodeling and pathologic hypertrophy. Hospital Practice. 1991 Jan 1;26(4):73-80.
Weber, Karl ; Brilla, C. G. ; Janicki, J. S. / Myocardial remodeling and pathologic hypertrophy. In: Hospital Practice. 1991 ; Vol. 26, No. 4. pp. 73-80.
@article{34a521b7cdec4b938d322d874681327a,
title = "Myocardial remodeling and pathologic hypertrophy",
abstract = "The hallmark of myocardial hypertrophy associated with congestive failure is interstitial fibrosis. How does the fibrosis develop, and what can be done about it? Hormonal and hemodynamic factors are examined. Experimental studies with ACE inhibitors or aldosterone receptor antagonists suggest that the fibrosis may be prevented or reversed.",
author = "Karl Weber and Brilla, {C. G.} and Janicki, {J. S.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "26",
pages = "73--80",
journal = "Hospital practice (1995)",
issn = "2154-8331",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Myocardial remodeling and pathologic hypertrophy

AU - Weber, Karl

AU - Brilla, C. G.

AU - Janicki, J. S.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The hallmark of myocardial hypertrophy associated with congestive failure is interstitial fibrosis. How does the fibrosis develop, and what can be done about it? Hormonal and hemodynamic factors are examined. Experimental studies with ACE inhibitors or aldosterone receptor antagonists suggest that the fibrosis may be prevented or reversed.

AB - The hallmark of myocardial hypertrophy associated with congestive failure is interstitial fibrosis. How does the fibrosis develop, and what can be done about it? Hormonal and hemodynamic factors are examined. Experimental studies with ACE inhibitors or aldosterone receptor antagonists suggest that the fibrosis may be prevented or reversed.

UR - http://www.scopus.com/inward/record.url?scp=0025809181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025809181&partnerID=8YFLogxK

M3 - Review article

VL - 26

SP - 73

EP - 80

JO - Hospital practice (1995)

JF - Hospital practice (1995)

SN - 2154-8331

IS - 4

ER -